Pfizer C4471001 (BRAF V600): Solid Tumors
What is the Purpose of this Study?
If you choose to join this study you will:
-Take the study drug (PF-07284890) by mouth 1 to 2 times a day
-Have a full eye examination
-Have physical exams, blood and urine tests.
-Have imaging scans (CT and/or MRI)
Some people will also:
-Take Binimetinib by mouth 2 times a day
-Take the study drug (PF-07284890) by mouth 1 to 2 times a day
-Have a full eye examination
-Have physical exams, blood and urine tests.
-Have imaging scans (CT and/or MRI)
Some people will also:
-Take Binimetinib by mouth 2 times a day
What is the Condition Being Studied?
Advanced solid tumors (including primary brain)
Who Can Participate in this Study?
Adults with BRAF V600 mutant advanced solid tumors with and without brain involvement.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out what the safest and most effective dose of the study drug (PF-07284890) is when given alone or in combination with Binimetinib.
Study Details
Full Title
A Two-Part, Phase 1a/b, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy of PF-07284890 (ARRY-461) in Participants with BRAF V600-Mutant Solid Tumors With and Without Brain Involvement
Principal Investigator
Protocol Number
IRB:
PRO00106594
NCT:
NCT04543188
ClinicalTrials.gov
View on ClinicalTrials.gov